Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by JAK-STAT pathway activation and epigenetic alterations.
• Histone deacetylase inhibitors (HDACIs) are effective in MPN treatment but have dose-limiting toxicities.
• Epigenetic modifications represent a targetable mechanism in MPN pathogenesis.

Purpose of the Study:

• To investigate the therapeutic effects of vorinostat, an HDACI, on primary MPN cells.
• To explore the role of reactive oxygen species (ROS) in vorinostat-induced apoptosis.
• To evaluate the synergistic potential of combining HDACIs with antioxidant agents for MPN treatment.

Main Methods:

• Treatment of primary MPN cells with vorinostat.
• Analysis of gene expression related to apoptosis, cell cycle, inflammation, and signaling.
• Measurement of reactive oxygen species (ROS) levels.
• In vitro combination therapy with vorinostat and antioxidant agents.

Main Results:

• Vorinostat modulated the expression of key cellular processes, leading to decreased MPN cell viability.
• Vorinostat treatment reduced reactive oxygen species (ROS) levels, which promoted apoptosis.
• Combining vorinostat with antioxidants resulted in synergistic enhancement of MPN cell apoptosis.

Conclusions:

• Vorinostat induces apoptosis in MPN cells through modulation of gene expression and reduction of ROS.
• Reducing ROS levels enhances vorinostat-induced apoptosis in MPN cells.
• Combining HDACIs with ROS-reducing agents presents a promising therapeutic strategy for treating MPNs.